Hospital Acquired Bacterial Infections Market to 2016 - Increasing Antibiotic Resistance and Increasing Population of Critically Ill Patients To Drive Growth - GBI Research Reports

Hospital Acquired Bacterial Infections Market to 2016 - Increasing Antibiotic Resistance and Increasing Population of Critically Ill Patients To Drive Growth

Hospital Acquired Bacterial Infections Market to 2016 - Increasing Antibiotic Resistance and Increasing Population of Critically Ill Patients To Drive Growth - GBI Research Reports
Hospital Acquired Bacterial Infections Market to 2016 - Increasing Antibiotic Resistance and Increasing Population of Critically Ill Patients To Drive Growth
Published Dec 31, 2010
97 pages — Published Dec 31, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research 'Hospital Acquired Bacterial Infections Market to 2016 - Increasing Antibiotic Resistance and Increasing Population of Critically Ill Patients To Drive Growth'. The report provides in-depth analysis of drivers and barriers that impact the global hospital acquired bacterial infections (HABI) market. The report analyzes the markets for hospital acquired bacterial infections in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

Scope

The scope of this report includes:
- Annualized market data for the HABI market from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including UTI, Pneumonia, SSI and BSI.
- Analysis of the HABI market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the HABI market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer, Eli Lily, Astrazeneca, Hoffman-La-Roche, Abbott, Novo Nordisk and Warner and Chilcott.
- Key M&A activities, licensing agreements, that have taken place since 2004 in HABI market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

  
Source:
Document ID
GBIHC060MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents37
1.1 List of Tables52
1.2 List of Figures73
2 Global Hospital Acquired Bacterial Infections Market: Introduction 101
2.1 GBI Research Report Guidance101
3 Global Hospital Acquired Bacterial Infections Market: Market Overview118
Introduction111
3.2 Revenue Forecasts for the Global Hospital Acquired Bacterial Infections Market121
3.2.1 Sales Value121
3.2.2 Annual Cost of Therapy131
3.2.3 Treatment Usage Patterns141
3.2.3.1 Diseased Population151
3.2.3.2 Diagnosed Population161
3.2.3.3 Prescription Population171
3.3 Hospital Acquired Bacterial Infections Market Drivers181
Steady Increase in Elderly and Immuno-Suppressed Population181
3.3.2 Increase in Average Number of Days Spent In Hospitals 181
3.3.3 Patent Expiries of Branded Drugs Will Make Them More Affordable 181
3.4 Hospital Acquired Bacterial Infections Market Restraints181
3.4.1 Increased Penetration of Generics Pose a Serious Threat for Primary Manufacturers181
3.4.2 Increased Anti-bacterial Surveillance in Hospitals181
4 Global Hospital Acquired Bacterial Infections Market: Therapeutic Landscape1935
4.1 Hospital Acquired Urinary Tract Infections (UTI) Market191
4.1.1 Introduction191
Sales Value192
4.1.3 Annual Cost of Therapy211
4.1.4 Treatment Usage Patterns221
4.1.4.1 Diseased Population231
4.1.4.2 Diagnosed Population241
4.1.4.3 Prescription Population251
Market Share by Geography262
4.2 Hospital Acquired Bacterial Pneumonia Market281
Introduction281
4.2.2 Sales Value282
4.2.3 Annual Cost of Therapy301
4.2.4 Treatment Usage Patterns311
Diseased Population321
4.2.4.2 Diagnosed Population331
4.2.4.3 Prescription Population 341
4.2.5 Market Share by Geography352
4.3 Hospital Acquired Bacterial Surgical Site Infections Market371
4.3.1 Introduction371
4.3.2 Sales Value371
4.3.3 Annual Cost of Therapy381
4.3.4 Treatment Usage Patterns391
4.3.4.1 Diseased Population401
4.3.4.2 Diagnosed Population411
4.3.4.3 Prescription Population421
4.3.5 Market Share by Geography432
4.4 Hospital Acquired Bacterial Blood Stream Infections (BSI) Market451
4.4.1 Introduction 451
Sales Value451
4.4.3 Annual Cost of Therapy461
4.4.4 Treatment Usage Patterns471
4.4.4.1 Diseased Population481
4.4.4.2 Diagnosed Population491
4.4.4.3 Prescription Population501
4.4.5 Market Share by Geography513
5 Global Hospital Acquired Bacterial Infections Market: Geographical Landscape5420
5.1 Geographical Break-up542
5.2 The US561
5.2.1 Sales Value561
5.2.2 Annual Cost of Therapy571
5.2.3 Treatment Usage Patterns581
5.2.3.1 Diseased Population591
5.2.3.2 Diagnosed Population601
5.2.3.3 Prescription Population 611
5.3 Top Five Countries in Europe621
5.3.1 Sales Value621
5.3.2 Annual Cost of Therapy631
5.3.3 Treatment Usage Patterns641
5.3.3.1 Diseased Population651
5.3.3.2 Diagnosed Population661
5.3.3.3 Prescription Population 671
5.4 Japan681
5.4.1 Sales Value681
5.4.2 Annual Cost of Therapy691
5.4.3 Treatment Usage Patterns701
5.4.3.1 Diseased Population711
5.4.3.2 Diagnosed Population721
5.4.3.3 Prescription Population 731
6 Global Hospital Acquired Bacterial Infections: Pipeline Analysis746
6.1 Profiles of Key Late Stage Drugs741
6.1.1 NVC-422741
6.1.1.1 Overview741
6.1.1.2 Mechanism of Action741
6.1.1.3 Clinical Study Details741
6.1.2 IC-43751
6.1.2.1 Overview751
6.1.2.2 Mechanism of Action751
6.1.2.3 Clinical Study Details751
6.1.3 Torizolid 761
6.1.3.1 Overview761
6.1.3.2 Mechanism of Action761
6.1.3.3 Clinical Study Details761
6.1.4 KBPA-101771
6.1.4.1 Overview771
6.1.4.2 Mechanism of Action771
6.1.4.3 Clinical Study Details781
6.1.5 hLF1-11 781
6.1.5.1 Overview781
6.1.5.2 Mechanism of Action781
6.1.5.3 Clinical Study Details791
6.2 Pipeline Drugs by Phase of Development791
7 Global Hospital Acquired Bacterial Infections Market: Competitive Landscape805
7.1 Competitive Profiling801
7.1.1 Johnson &Johnson (J&J)801
7.1.1.1 Overview801
7.1.1.2 Product Portfolio801
7.1.2 Pfizer811
7.1.2.1 Overview811
7.1.2.2 Product Portfolio821
7.1.3 Cubist Pharmaceuticals831
7.1.3.1 Overview831
7.1.3.2 Product Portfolio831
7.1.4 Bayer831
7.1.4.1 Overview831
7.1.4.2 Product Portfolio841
8 Global Hospital Acquired Bacterial Infections Market: Strategic Consolidations857
8.1 Overview851
M&A Deals by Geography851
8.3 M&A Deals by Value 851
8.4 M&A Deals by Deal Type861
8.4.1 AstraZeneca Completed the Acquisition of Novexel SA in March 2010871
8.4.2 Pharma Omnium International Acquired Mutabilis in July 2009871
8.4.3 Hilton Pharma Merges with Sami Pharmaceuticals in November 2008871
8.4.4 Phylogica Acquired Additional 63% Stake in Dynamic Microbials in November 2008871
8.4.5 Sanofi Pasteur Acquired Acambis in September 2008871
8.5 R&D Licensing Agreements881
8.5.1 Major Licensing Agreements891
8.5.1.1 Anacor Pharmaceuticals Enters Into Licensing Agreement with GlaxoSmithKline in July 2010891
8.5.1.2 e-Therapeutics Enters Into Licensing Agreement with Khandelwal Laboratories in February 2009901
8.5.1.3 Basilea Pharmaceutica Enters Into Licensing and Development Agreement with Cilag AG International in February 2005901
8.5.1.4 Astellas Pharma Enters Into Licensing Agreement with Theravance in November 2005901
8.5.1.5 MedImmune Enters Into License Agreement with GlaxoSmithKline in August 2005911
9 Global Hospital Acquired Bacterial Infections Market: Appendix926
9.1 Market Definitions921
9.2 Abbreviations921
9.3 Research Methodology934
9.3.1 Coverage 931
9.3.2 Secondary Research931
9.3.3 Primary Research931
9.3.4 Forecasts941
9.3.4.1 Epidemiology-based Forecasting942
9.3.5 Expert Panel Validation961
9.4 Contact Us971
9.5 Disclaimer971
9.6 Sources971

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Hospital Acquired Bacterial Infections Market to 2016 - Increasing Antibiotic Resistance and Increasing Population of Critically Ill Patients To Drive Growth" Dec 31, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Hospital-Acquired-Bacterial-Infections-Market-to-2016-Increasing-Antibiotic-Resistance-and-Increasing-Population-of-Critically-Ill-Patients-To-Drive-Growth-2115-148>
  
APA:
GBI Research Reports. (2010). Hospital Acquired Bacterial Infections Market to 2016 - Increasing Antibiotic Resistance and Increasing Population of Critically Ill Patients To Drive Growth Dec 31, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Hospital-Acquired-Bacterial-Infections-Market-to-2016-Increasing-Antibiotic-Resistance-and-Increasing-Population-of-Critically-Ill-Patients-To-Drive-Growth-2115-148>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.